Ragweed sublingual tablet immunotherapy: part I – evidence-based clinical efficacy and safety
| Autor: | Peter S. Creticos, Oliver Pfaar |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Ragweed Allergen immunotherapy medicine.medical_specialty Evidence-based practice medicine.medical_treatment Immunology Administration Sublingual medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Allergen medicine Humans Immunology and Allergy Conjunctivitis Allergic Asthma biology Plant Extracts business.industry Rhinitis Allergic Seasonal Allergen extract Immunotherapy Allergens Antigens Plant medicine.disease biology.organism_classification Dermatology Clinical trial Treatment Outcome 030104 developmental biology 030228 respiratory system Oncology Desensitization Immunologic Pollen Ambrosia business Tablets |
| Zdroj: | Immunotherapy. 10:605-616 |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt-2017-0186 |
| Popis: | Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|